Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.89 USD
Change Today -0.14 / -4.62%
Volume 928.0K
ATNM On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

actinium pharmaceuticals inc (ATNM) Snapshot

Open
$3.10
Previous Close
$3.03
Day High
$3.15
Day Low
$2.78
52 Week High
06/2/14 - $13.70
52 Week Low
05/18/15 - $2.31
Market Cap
103.6M
Average Volume 10 Days
605.0K
EPS TTM
$-0.38
Shares Outstanding
35.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTINIUM PHARMACEUTICALS INC (ATNM)

Related News

No related news articles were found.

actinium pharmaceuticals inc (ATNM) Related Businessweek News

No Related Businessweek News Found

actinium pharmaceuticals inc (ATNM) Details

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies. Its products include Actimab-A, an antibody-drug construct, which includes monoclonal antibody Lintuzumab and alpha emitting radioisotope actinium 225; and is in multicenter Phase I/II clinical trials for acute myeloid leukemia (AML). The company also offers Iomab-B, an antibody-drug construct that comprises the BC8 monoclonal antibody and beta emitting radioisotope iodine 131, and is used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its Iomab-B is in preparation for a Phase III multicenter clinical trial for bone marrow conditioning for HSCT in relapsed and refractory AML patients. The company was founded in 2000 and is based in New York, New York.

12 Employees
Last Reported Date: 03/16/15
Founded in 2000

actinium pharmaceuticals inc (ATNM) Top Compensated Officers

Chief Executive Officer, President, Interim C...
Total Annual Compensation: $442.0K
Chief Operating Officer and Chief Medical Off...
Total Annual Compensation: $348.4K
Compensation as of Fiscal Year 2014.

actinium pharmaceuticals inc (ATNM) Key Developments

Actinium Pharmaceuticals, Inc. Announces Clinical Update on Actimab A at Upcoming 2015 ASCO Annual Meeting

Actinium Pharmaceuticals, Inc. announced the upcoming poster and abstract at ASCO 2015, the 51st Annual Meeting of American Society of Clinical Oncology, to be held in Chicago on May 29 - June 2. Data will be presented from the Company's ongoing multi-center Phase 1/2 Study for Actimab-A for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) in elderly patients. Clinical data from the first three cohorts will be discussed. Cohort 3, which included 3 additional patients, demonstrated no dose limiting toxicities in patients older than 60 and up to 87 years of age who were not eligible for currently approved therapies. Two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery (CRi). These responses were documented in the settings of high pre-treatment leukemia burdens of up to 88% in the bone marrow. In the previous cohort treated at a lower dose level of Actimab-A, one patient achieved CRi. The Company also recently announced that it began the fourth and last cohort (2.0 Ci/kg per dose) in the Phase I portion of this trial. //st Title: Phase I trial of a-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) &low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).

Actinium Pharmaceuticals, Inc. Appoints Jeng-Dar Yang as Vice President of Pharmaceutical Development

Actinium Pharmaceuticals, Inc. announced the appointment of Jeng-Dar Yang, Ph.D. to the position of Vice President of Pharmaceutical Development effective May 4, 2015. Dr. Yang brings with him 23 years of biotechnology experience in increasingly senior roles. Dr. Yang joins Actinium Pharmaceuticals from Immunomedics Inc. where he was the Executive Director, Cell Culture Production.

Actinium Pharmaceuticals Opens Enrollment for the Fourth and Final Cohort for Phase I/II Trial in Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. announced that the company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the fourth cohort, who, in keeping with trial protocol, will be injected with two doses 4 to 7 days apart of the company's investigational new drug Actimab-A at a higher activity level of 2.0 µCi/kg per dose. In the previously completed third cohort in which patients received two doses of Actimab-A at 1.5 µCi/kg per dose two out of three Actimab-A treated patients achieved complete remission with different degrees of hematological recovery (CRi). These responses were documented in the settings of high pre-treatment leukemia burdens of up to 80% in the bone marrow. In the second cohort treated at a lower dose level of Actimab-A of 1.0 µCi/kg per dose, one patient achieved CRi. The trial is a prospective, open-label study, designed to determine the safety and efficacy of Actimab-A in newly diagnosed AML patients who cannot tolerate current high dose chemotherapeutic regimens. Actinium previously announced positive interim data from the ongoing Phase 1/2 trial of Actimab-A in older patients with newly diagnosed Acute Myeloid Leukemia. Most notably, median overall survival of the seven secondary AML patients (with prior myelodysplastic syndrome, or MDS) in the study was 9.1 months, which compares favorably to historical norms of 2 to 5 months depending on the treatment modality. Older AML patients are already higher risk, with secondary AML patients considered to have the more severe and less treatable form of AML, and as a consequence have shorter expected survival.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATNM:US $2.89 USD -0.14

ATNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ATNM.
View Industry Companies
 

Industry Analysis

ATNM

Industry Average

Valuation ATNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTINIUM PHARMACEUTICALS INC, please visit www.actiniumpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.